Podcasts about tumor microenvironment

(2:40) - Cancer-on-a-chip technology advances our understanding of how cancer operatesThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn more about the role of field programmable gate arrays (FPGAs) in the medical world! Become a founding reader of our newsletter: http://read.thenextbyte.com/ As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.

Exploring the stress-cancer link—real, or unduly stigmatizing for people with cancer? Is coffee the most chemically-treated food? Is there a link between fluoride and pineal gland dysfunction? TV ads for oral supplement for dry eyes tout a dubious formula (and what could work better); Could meat make America healthy again?

Physician Ash Alizadeh has seen the future of disease diagnosis and monitoring. It is coursing through every patient's veins. Traditionally, biopsies have required invasively gathering tissue – from a lung, a liver, or a fetus. Now it's possible to look for disease without surgery. The DNA is sitting there in the bloodstream, Alizadeh tells host Russ Altman, as they preview the age of liquid biopsies on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Ash A. Alizadeh, MD/PhDConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Ash Alizadeh, a faculty member at Stanford University in Oncology and Medicine.(00:03:39) What is a Liquid Biopsy?Accessing tissues non-invasively using bodily fluids.(00:04:31) Detecting Cancer with Liquid BiopsiesHow localized cancers can be detected through blood samples.(00:06:32) The Science Behind Cancer DNA DetectionThe differences between normal and cancer DNA(00:09:51) How Liquid Biopsy Technology WorksThe technologies behind detecting cancer-related DNA differences.(00:12:36) Advances in Liquid BiopsyNew detection approaches using non-mutant molecules and RNA.(00:14:10) RNA as a Real-Time Tumor MarkerHow RNA reveals active tumor processes and drug resistance.(00:15:55) Tracking Cancer ReccurenceUsing tumor-informed panels to monitor cancer recurrence.(00:16:28)  Adapting to Tumor EvolutionWhy core mutations remain detectable despite cancer changes.(00:17:57) Stability of DNA, RNA, and MethylationComparing durability and reliability of different biomarkers.(00:20:49) Listener Question: Early Cancer DetectionDaniel Kim asks about pre-cancer detection and its potential impact.(00:24:44) Liquid Biopsy in ImmunotherapyUsing liquid biopsy to track and improve immune-based treatments.(00:27:35) Monitoring CAR T-Cell TherapyHow liquid biopsy helps assess immune cell expansion.(00:32:02) EPIC-Seq: Inferring RNA from DNAUsing DNA fragmentation to predict gene expression in tumors.(00:34:49) Targeting Tumor Support SystemsTreatment strategies disrupting the tumor microenvironment.(00:35:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

When it comes to living a healthy, full life, you must take inventory of your daily routine—it can inform the current and future state of your health. This week, I'm joined by Dr. Leigh Erin Connealy, a leading expert in integrative medicine, who is known for addressing the root cause of disease, including cancer. We sat down to discuss cancer prevention, early detection, and how key lifestyle changes can treat and prevent disease.  In this episode, you'll discover: Why Cancer Diagnoses Are More Common Today: Since 1990, there's been an 80% increase in cancer among young people especially. Dr. Connealy attributes this to a variety of factors—pollution in the air, water, and food supply, people leading more sedentary lives, and the rise of antibiotics—that weren't as prevalent decades ago. "It's toxic everywhere, and it doesn't matter where you eat, what you eat, it's present." How to Prevent Disease: In that same vein, there are steps you can take to help your body help you. It all starts with how you live your 24-hour day, says Dr. Connealy. As for what you can do to Take Back Your Health™? Address your emotional state, detoxify, go outside, exercise, boost your vitamin C intake, clock in quality sleep, eat a paleo diet, and limit daily stressors wherever possible. "Your body is miraculously made. It's constantly trying to take care of you," adds Dr. Connealy.  Early Detection Signs: While Dr. Connealy says bloodwork doesn't typically reveal a cancer diagnosis, there are markers you should be cognizant of. If your C reactive protein ("a nonspecific marker for inflammation"), for example, is over 0.5, that is something to be weary of because "inflammation is the precursor to all diseases," says Dr. Connealy, who also emphasizes the importance of tracking levels of vitamin D, which influences over 3,000 genes. 00:00 Rising Cancer Rates: A Modern Epidemic 02:46 Dr. Connealy's Personal Journey 09:47 The Importance of Prevention and Early Detection 15:30 Practical Steps for Health and Wellness 30:20 Understanding Hemoglobin A1C and Nagalase 30:52 Immune System and Hormone Testing 31:26 Cancer Profile and Liquid Biopsies 32:53 Bioenergetic Testing and Chinese Medicine 35:30 Tumor Microenvironment and Conventional Oncology 37:53 Integrative Approaches to Cancer Treatment 42:31 Low Dose Chemotherapy and Insulin Potentiation 47:22 The Role of Fasting and Lifestyle Changes 52:13 QT Scan: A Kinder Breast Evaluation Connect with Dr. Myers: Website: https://www.amymyersmd.com/ Newsletter: https://www.amymyersmd.com/ec/guide-to-leaky-gut Facebook: https://www.facebook.com/AmyMyersMD Instagram: https://www.instagram.com/amymyersmd/ Connect with Dr. Connealy: Website: https://www.connealymd.com/ Facebook: https://www.facebook.com/ConnealyMD/ Instagram: https://www.linkedin.com/in/leigherinconnealy/ Twitter: https://x.com/drconnealymd Podcast - Cancer Conversation: https://cancercenterforhealing.com/webinar/ Books - The Cancer Revolution: https://amymd.io/4

Have you ever wondered how our cancer metastasizes? Why is it that some treatments just don't work? Can we as patients living with MBC alter cellular level activity? In this episode, you will hear the answers to these questions and more. Join us as we take a step back to the basics of tumor microenvironment with our guest, Dr. Amy Beumer, who will break down the science to smaller, digestible bites. In this lively discussion, Dr. Amy explains the how and the why of this tough topic. You will hear her say “This is fun” and use engaging, relatable metaphors like “Picture your neighborhood and that one neighbor…..”  By the end, I assure you that you'll walk away with a deeper understanding of tumor microenvironment than when you started. Pull up a chair, listen in your car or on your daily walk, we are with you wherever you listen to your podcasts. Terms and other resources are provided  in the episode notes on the episode web page,  www.ourmbclife.org/episodes/tumor-microenvironment-dr-beumer.

David Mazzo, President and CEO of Lisata Therapeutics, has a lead program focused on metastatic pancreatic ductal adenocarcinoma. The Lisata CendR Platform and drug certepetide efficiently augment the effects of chemotherapy and immunotherapies in the tumor microenvironment. Based on early findings, the future of cancer treatment may involve combining existing therapies with certepetide to personalize treatment for most solid tumors. David explains, "At Lisata, we're developing therapies to combat a challenging problem in the medical field today, which is the effective treatment of solid tumors. Solid tumors are very difficult to treat for two very simple reasons. On the one hand, these tumors generate a layer of cells around them that acts as a physical barrier. It's called the tumor stroma, and it prevents the penetration of many anti-cancer medicines into the tumor, which is why you often don't get the kind of results that one would expect." "The other obstacle these tumors present is that they generate or express a tumor microenvironment that is immunosuppressive, which helps the tumor hide from your innate immune system. It helps it not respond very well to externally administered immunotherapies. When you combine these two challenges, you end up with a set of diseases that remains an enigma in medical science today."   "So our therapy at Lisata called certepetide, our lead product, actually combines the ability to target and penetrate tumors more effectively for co-administered anti-cancer drugs with the ability to modify the tumor microenvironment, making it more immunoreceptive and therefore more likely to respond to your immune system and immunotherapies."  #Lisata #Oncology #Cancer #SolidTumors #Immunotherapies #TumorMicroEnvironment lisata.com Download the transcript here

David Mazzo, President and CEO of Lisata Therapeutics, has a lead program focused on metastatic pancreatic ductal adenocarcinoma. The Lisata CendR Platform and drug certepetide efficiently augment the effects of chemotherapy and immunotherapies in the tumor microenvironment. Based on early findings, the future of cancer treatment may involve combining existing therapies with certepetide to personalize treatment for most solid tumors. David explains, "At Lisata, we're developing therapies to combat a challenging problem in the medical field today, which is the effective treatment of solid tumors. Solid tumors are very difficult to treat for two very simple reasons. On the one hand, these tumors generate a layer of cells around them that acts as a physical barrier. It's called the tumor stroma, and it prevents the penetration of many anti-cancer medicines into the tumor, which is why you often don't get the kind of results that one would expect." "The other obstacle these tumors present is that they generate or express a tumor microenvironment that is immunosuppressive, which helps the tumor hide from your innate immune system. It helps it not respond very well to externally administered immunotherapies. When you combine these two challenges, you end up with a set of diseases that remains an enigma in medical science today."   "So our therapy at Lisata called certepetide, our lead product, actually combines the ability to target and penetrate tumors more effectively for co-administered anti-cancer drugs with the ability to modify the tumor microenvironment, making it more immunoreceptive and therefore more likely to respond to your immune system and immunotherapies."  #Lisata #Oncology #Cancer #SolidTumors #Immunotherapies #TumorMicroEnvironment lisata.com Listen to the podcast here

Sabina Kaczanowska's research focus is to understand the role of the immune system in shaping the microenvironment of metastasis during cancer progression. Specifically, she is investigating how myeloid cells orchestrate the immunosuppressive program in the pre-metastatic niche and how we can apply this knowledge of myeloid biology to design new immunotherapeutic strategies for the treatment of solid tumors. She joined us on OsteoBites to discuss her recently published paper on Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.https://pubmed.ncbi.nlm.nih.gov/38134936/Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. The NCI conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with osteosarcoma and neuroblastoma. Patient samples were evaluated by multi-dimensional proteomic, transcriptomic, and epigenetic analyses. The data uncover mediators of CAR-T biology and correlates of expansion that could be utilized to advance immunotherapies for solid tumor patients.https://clinicaltrials.gov/study/NCT02107963Dr. Sabina Kaczanowska received her Ph.D. in Molecular Microbiology and Immunology from the University of Maryland, Baltimore for her dissertation work on T-cell immunotherapy at the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center. She joined the Tumor Microenvironment and Metastasis Section of the Pediatric Oncology Branch at the National Cancer Institute as a postdoctoral fellow in 2017 with Dr. Rosandra Kaplan. Dr. Kaczanowska was appointed as a Staff Scientist in the Pediatric Oncology Branch in 2022 to continue her work evaluating the responses of solid tumor patients to immunotherapy and translating new immuno-oncology approaches into the clinic.

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally active therapeutics designed to be active only within the low-pH tumor microenvironment.  Current pipeline candidates are designed to be active only within the low-pH tumor microenvironment and show potential to overcome the challenges of VISTA, a promising checkpoint target. John explains, "As an industry, we have some tough choices. Other strategies, both within and outside of IO, have made much better progress in targeting which patients will respond and which patients won't respond to treatment. Those are decisions that we have to make as an industry to keep up." "The second one I would point to is that we're now in a decade after the first immuno-oncology drug approval. And so, we have a whole generation of patients now that have been exposed to checkpoint therapy, and that are now many of whom resistant to checkpoint therapy. We call that acquired resistance. And so the game has really changed. It's an open question: whether the first PD-1 drugs would be approved today if all of those patients had been treated with some other checkpoint therapy prior to it raises the bar. This means new strategies are needed to treat patients with acquired resistance to immunotherapy."   "One of the interesting things about VISTA is that it does play a key role in the tumor microenvironment. The tumor microenvironment is unique because it's an environment inside the body in which cells proliferate very rapidly. That leads to a whole host of subsequent changes that affect the outcome of therapy, the fact that when cells are dividing rapidly, the pH in the area tends to drop, and it becomes more acidic. And that's directly related to the function of VISTA. It's one of the things that makes VISTA unique because VISTA is only activated as an immune checkpoint under lower pH conditions." #SenseiBio #ImmunOncology #PatientSelection #Immunotherapy #Cancer #Tumors #ImmuneCheckpointTargets #VISTA SenseiBio.com Listen to the podcast here

John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally active therapeutics designed to be active only within the low-pH tumor microenvironment.  Current pipeline candidates are designed to be active only within the low-pH tumor microenvironment and show potential to overcome the challenges of VISTA, a promising checkpoint target. John explains, "As an industry, we have some tough choices. Other strategies, both within and outside of IO, have made much better progress in targeting which patients will respond and which patients won't respond to treatment. Those are decisions that we have to make as an industry to keep up." "The second one I would point to is that we're now in a decade after the first immuno-oncology drug approval. And so, we have a whole generation of patients now that have been exposed to checkpoint therapy, and that are now many of whom resistant to checkpoint therapy. We call that acquired resistance. And so the game has really changed. It's an open question: whether the first PD-1 drugs would be approved today if all of those patients had been treated with some other checkpoint therapy prior to it raises the bar. This means new strategies are needed to treat patients with acquired resistance to immunotherapy."   "One of the interesting things about VISTA is that it does play a key role in the tumor microenvironment. The tumor microenvironment is unique because it's an environment inside the body in which cells proliferate very rapidly. That leads to a whole host of subsequent changes that affect the outcome of therapy, the fact that when cells are dividing rapidly, the pH in the area tends to drop, and it becomes more acidic. And that's directly related to the function of VISTA. It's one of the things that makes VISTA unique because VISTA is only activated as an immune checkpoint under lower pH conditions." #SenseiBio #ImmunOncology #PatientSelection #Immunotherapy #Cancer #Tumors #ImmuneCheckpointTargets #VISTA SenseiBio.com Download the transcript here

Rachel Offenbacher, MD, is an attending physician at Children's Hospital at Montefiore (CHAM) and Assistant Professor, Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation at Montefiore Einstein. She joins us on OsteoBites to share her work on targeting urea cycle dysfunction to prevent and treat osteosarcoma metastasis.Since joining the Montefiore team, Dr. Offenbacher's clinical focus has been pediatric sarcomas. As a member of a translational sarcoma research lab, Dr. Offenbacher is fascinated by the ability to explore the biological processes behind novel therapeutic approaches before they are used in the clinic. Her research focuses on utilizing difluoromethylornithine to prevent and treat metastatic osteosarcoma. She has seen impressive results in her in vitro and in vivo models and is working to initiate a clinical trial. She is simultaneously working on a project funded by the American Association of Cancer Research, Targeting the Tumor Microenvironment of Metastasis to Treat Metastatic Ewing Sarcoma, which is demonstrating promising results. Dr. Offenbacher's work has been published in numerous peer-reviewed journals and presented nationally and internationally. Dr. Offenbacher is board certified in General Pediatrics by the American Board of Pediatrics. She is a member of several professional organizations, including the American Association for Cancer Research, the Children's Oncology Group and the American Society of Pediatric Hematology/Oncology. Dr. Offenbacher is also an active member of the National Pediatric Cancer Foundation. In 2020 and 2022, she won the Leo M. Davidoff Society Teaching Award; in 2022, she won the Pediatric Research Day Oral Presentation Award from CHAM. Dr. Offenbacher is a volunteer pediatric oncologist at Camp Simcha, a residential camp for children with cancer.

In this bonus episode of Blood Podcast, Associate Editor, Dr. Freda Stevenson is joined by Drs. Karin Tarte, Andrea Ratke, and Leandro Cerchietti to discuss the Review Series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas. Find the full review series in Blood Journal volume 143 issue 12. 

Pancreatic ductal adenocarcinoma (PDA), a common type of pancreatic cancer, has proven to be largely resistant to immunotherapy, a treatment that uses the body's immune system to fight cancer. Despite numerous successful pre-clinical trials using sophisticated PDA mouse models, clinical trials have failed to show a significant improvement in survival. In a recent editorial, researchers Brian Diskin, Sarah Schwartz and George Miller from Trinity Health of New England shed light on the complex interplay between the immune system and pancreatic cancer. Their paper was published in Oncotarget on April 24, 2023, and entitled, “The critical immune basis for differential responses to immunotherapy in primary versus metastatic pancreatic cancer.” Tumor Microenvironment and Liver Metastasis: Challenges in Pancreatic Cancer The authors attribute PDA immunotherapy resistance to the unique characteristics of the tumor microenvironment (TME). The TME is often hypoxic and fibrotic, making it inaccessible to immune cells. Furthermore, the immune cells that do infiltrate the TME often have tolerogenic features, meaning they are more likely to tolerate the presence of cancer cells rather than attack them. PDA most commonly metastasizes to the liver, an organ known for its immune tolerance. The liver is home to a diverse array of innate immune populations, including NK cells, Kupfer cells, NKT cells, and double negative T cells. Despite this, the liver is the most common location for metastasis from gastrointestinal cancers. “It is an unfortunate fact that all failed clinical trials assessing immunotherapeutic efficacy were conducted in metastatic PDA, whereas basic preclinical investigations are usually performed in primary PDA using genetically engineered mouse models. We postulated that this dichotomy may explain the gap between preclinical promise and ultimate clinical failure.” Full blog - https://www.oncotarget.org/2023/11/16/immunotherapy-response-in-primary-vs-metastatic-pancreatic-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28373 Correspondence to - George Miller - gedalyamil@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28373 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic cancer, liver metastasis, immunnotherapy About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.

Reference Cancers (Basel). 2021. Apr; 13(8): 1850. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message

Dr. Christian Capitini is an associate professor and the Jean R. Finley Professor of Pediatric Hematology and Oncology. He serves as co-leader of the Developmental Therapeutics Program at the University of Wisconsin Carbone Cancer Center and director of clinical innovation at the Forward BIO Institute. He has received many awards for his clinical and research contributions, including the Department of Pediatrics Gerard B. Odell Research Award, the Outstanding New Member Science Award from the Society for Pediatric Research (SPR), and the Janet Rowley Award from the Jonas Center Cellular Therapy Symposium at the University of Chicago. Nationally, Dr. Capitini is an active member of the Society for Immunotherapy of Cancer (SITC) and serves as at-large director. Additionally, he serves on the executive board for the Pediatric Real World chimeric antigen receptor (CAR) T Consortium. Dr. Capitini leads an NIH-supported laboratory focusing on development of cell-based immunotherapies, including natural killer (NK) cells and CAR T cells, for the treatment of pediatric solid tumors. The Capitini Lab also develops alternatively activated macrophages for complications of bone marrow transplant, including graft-versus-host-disease (GVHD) and acute radiation syndrome. Dr. Capitini was one of the site principal investigators (PI) for the first multicenter CD19 CAR T cell trial, which led to the FDA approval of tisagenlecleucel-T (Kymriah) for relapsed/refractory B cell leukemia. Currently, he is site PI for a Kymriah trial related to the upfront treatment of high-risk B cell leukemia and for a multicenter GD2 CAR T cell trial for neuroblastoma and osteosarcoma through the Pediatric NCI-Cancer Immunotherapy Trials Network (CITN). He is also a sponsor and PI for a University of Wisconsin clinical trial expanding gamma delta T cells in vivo using zoledronate after alpha beta T cell depleted stem cell transplant. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

References Journal of Experimental & Clinical Cancer Research 2022.volume 41, Article number: 303. Protein Cell. 2021 Apr; 12(4): 240–260. J Cell Biol (2022) 221 (11): e202202011. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.28.538645v1?rss=1 Authors: Cheng, L., Wei, C., Dong, L., Xiong, S., Yu, P., Zhou, R. Abstract: Extensive research has been conducted on the heterogenicity of immune cells within the tumor microenvironment, like cancer cell heterogenicity, particularly with the emergence of single cell analysis. While inducing factors have been used to artificially alter immune cell fate in vitro and dynamic cancer cell plasticity has been recently discovered, it remains unknown whether tumor infiltrating immune cells acquire plasticity and dynamics that contribute to heterogenicity. In this study, we explored mitochondrial DNA mutation combining with chromosome single nucleotide polymorphism to construct phylogenetic trees of immune cells within multiple solid tumors, together with precise cell type and subtype definition based on single cell RNA sequencing data. Based on these lineage tracing landscapes, we systematically identified cell state transitions and fate changes among different immune cell subtypes and types within multiple solid tumors. Interestingly, immune cells demonstrated a high level of plasticity for transitioning between different states, transdifferentiating from one type to another or dedifferentiating to a progenitor stage, in varying frequencies across different cancers. Moreover, most of these cell state transitions and cell fate changes discovered here were previously unknown. The cell changes may arise from extrinsic growth factors and cytokines secreted by tumor microenvironment cells, but intrinsic genetic mutations, particularly those related to ribosomes, may also be involved. Our data reveal that immune cell complexity extends beyond heterogenicity and also encompasses plasticity similar to that of cancer cells. Understanding the underlying mechanism of these cell changes will help elucidate the role of immune cells in cancer development and manipulating the cell change direction may ultimately enhance the efficiency of current immunotherapy. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

References Current Oncology Reports. 2020. 1534-6269, May 15, Vol. 22, Issue 6. Cell. 2021 Dec 9; 184(25):6081–6100.e26. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and... The post iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies appeared first on VJHemOnc.

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and... The post iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies appeared first on VJHemOnc.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.26.522174v1?rss=1 Authors: Bartos, L. M., Kirchleitner, S. V., Kolabas, Z. I., Quach, S., Blobner, J., Mueller, S. A., Ulukaya, S., Hoeher, L., Horvath, I., Wind-Mark, K., Holzgreve, A., Ruf, V. C., Gold, L., Kunze, L. H., Kunte, S. T., Beumers, P., Antons, M., Zatcepin, A., Briel, N., Hoermann, L., Messerer, D., Bartenstein, P., Riemenschneider, M. J., Lindner, S., Ziegler, S., Herms, J., Lichtenthaler, S. F., Ertuerk, A., Tonn, J. C., von Baumgarten, L., Albert, N. L., Brendel, M. Abstract: Various cellular sources hamper interpretation of positron-emission-tomography (PET) biomarkers in the tumor microenvironment (TME). We developed immunomagnetic cell sorting after in vivo radiotracer injection (scRadiotracing) in combination with 3D-histology via tissue clearing to dissect the cellular allocation of PET signals in the TME. In SB28 glioblastoma mice, translocator protein (TSPO) radiotracer uptake per tumor cell was higher compared to tumor-associated microglia/macrophages (TAMs). Cellular radiotracer uptake was validated by proteomics and confirmed for in vitro samples of patients with glioblastoma. Regional agreement between PET signals and single cell tracer uptake predicted the individual cell distribution in 3D-histology. In consideration of cellular tracer uptake and cell type abundance, tumor cells were the main contributor to TSPO enrichment in glioblastoma, however proteomics identified potential PET targets highly specific for TAMs. Combining cellular tracer uptake measures with 3D-histology facilitates precise allocation of complex PET signal sources and will serve to validate novel TAM-specific radioligands. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this podcast, Dr Luca Roz and Dr Luca Varinelli discuss about the usefulness of decellularized extracellular matrix obtained from cell cultures or cancer patients-derived tissue fragments for investigating the cross-talk between cancer cells and microenvironment niches in basic and translational research.

Das maligne Melanom metastasiert bei jedem 5. Betroffenen. Doch Patient:innen überleben heute länger als jemals zuvor – bei Ansprechen auf die Immuntherapie. Was ist der aktuelle Stand in der Melanom-Therapie, welche Nebenwirkungen können auftreten – und zeichnet sich ein Nutzen des bundesweiten Hautkrebsscreenings ab? Mit dieser Podcastfolge mit Prof. Dr. Bastian Schilling und Dr. Patrick Schummer, Würzburg, im Gespräch mit Antje Blum und Dr. Astrid Heinl können Sie insgesamt 3 CME-Punkte* erwerben. * für registrierte Nutzer von www.journalonko.de, Start 7.9.22; 1 Jahr lang, in Kombination mit dem Beitrag „Aktuelle Therapiekonzepte beim malignen Melanom – Update 2022“ aus JOURNAL ONKOLOGIE 6/2022 Dieser Podcast ist eine Kooperation zwischen dem JOURNAL ONKOLOGIE und der Medical Tribune Onkologie • Hämatologie www.journalonko.de www.medical-tribune.de Fragen, Feedback und Themenvorschläge gerne an: o-ton-onkologie@medtrix.group Abkürzungen: TIL=Tumor-infiltrierende Lymphozyten PROTACs=PROteolysis TArgeting Chimeras PROMIT-Studie: Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy https://www.journalonko.de/studien/details/promit_nct04225390 Podcast-Empfehlungen: • stellvertretend für das Genre True Crime: "Schwarze Akte" https://podcasts.apple.com/de/podcast/schwarze-akte-true-crime/id1512453641 • „Impfen gegen Krebs – Welche Zukunft hat die peptidbasierte Immuntherapie?“ O-Ton Onkologie – der Podcast für Mediziner:innen. Gespräch mit Prof. Dr. Juliane Walz, Universitätsklinikum Tübingen, erschienen am 29.6.2022: https://soundcloud.com/o-ton-onkologie/impfen-gegen-krebs-welche-zukunft-hat-die-peptidbasierte-immuntherapie

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions. -- John A. Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. Dr. Ligon earned his medical degree from the Baylor College of Medicine in Houston. After he completed his residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, he pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute in Maryland. In the following years, he completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University. Dr. Ligon is board-certified in both general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. In addition to his numerous original research publications and editorial review appointments, he is a member of various professional societies, such as the Children's Oncology Group and the American Association for Cancer Research. Dr. Ligon has been honored with a variety of awards for his research skills and academic excellence. His research interests include immunotherapy, tumors and bloodstream infections.

Mai-Britt Zocca is the Founder, CEO, and President of IO Biotech, a clinical stage biopharmaceutical company headquartered in Denmark. They are developing immune modeling cancer therapies based on their T-win technology. Using these cancer vaccines, pre-existing T-cells are being directed in patients to attack and eliminate solid tumors. Mai-Britt explains, "Currently, we have a leading program that is in Phase 3. So, this is in first-line advanced melanoma. We have a breakthrough therapy designation granted by the FDA, based on the earlier data that we have seen in melanoma. Our targets also are able to be used in other cancer indications. We are not melanoma per se. We are already running trials in first-line solid tumors where we are including also lung, head, neck, and bladder cancer." "What we do is vaccinate, as I mentioned before, and the vaccination process is a combination of first a booster program, where we give vaccination or injections several times. Then we have a maintenance phase after that. This is where we see that after these vaccinations, where we vaccinate against the tumor environment, we generate the T-cells that can react towards the immune suppressive mechanisms that we know are hindering the effect of the T-cells in these patients." #IOBiotech #Melanoma #CancerVaccine #Immunotherapy #Cancer #ImmunoOncology IOBiotech.com Listen to the podcast here

Mai-Britt Zocca is the Founder, CEO, and President of IO Biotech, a clinical stage biopharmaceutical company headquartered in Denmark. They are developing immune modeling cancer therapies based on their T-win technology. Using these cancer vaccines, pre-existing T-cells are being directed in patients to attack and eliminate solid tumors. Mai-Britt explains, "Currently, we have a leading program that is in Phase 3. So, this is in first-line advanced melanoma. We have a breakthrough therapy designation granted by the FDA, based on the earlier data that we have seen in melanoma. Our targets also are able to be used in other cancer indications. We are not melanoma per se. We are already running trials in first-line solid tumors where we are including also lung, head, neck, and bladder cancer." "What we do is vaccinate, as I mentioned before, and the vaccination process is a combination of first a booster program, where we give vaccination or injections several times. Then we have a maintenance phase after that. This is where we see that after these vaccinations, where we vaccinate against the tumor environment, we generate the T-cells that can react towards the immune suppressive mechanisms that we know are hindering the effect of the T-cells in these patients." #IOBiotech #Melanoma #CancerVaccine #Immunotherapy #Cancer #ImmunoOncology IOBiotech.com Download the transcript here

Have you noticed there is so much news, yet there is so little productive conversations! That's where Your Weekly Tea comes in! This will be a show to discuss the latest stories, studies and events that you need to know for better health! (And sometimes this means dispelling the BS in recent news!This Weeks Tea:Between 1940 and now, nutrient levels in fruits, vegetables in UK reduced by 50%, says studyHope for acne sufferers as dermatologists identify possible link between key nutrient and skin conditionActivity-Based NIR Bioluminescence Probe Enables Discovery of Diet-Induced Modulation of the Tumor Microenvironment via Nitric OxideLinks to Probiotics:Should You Eat Wheat?Courtney Lyman - Health CoachInstagram: @courtneylyman_TikTok: @courtneylyman_

Dr. Huang is the Director of Center for Pediatric Immunotherapy in the Angie Fowler AYA Cancer Institute at UH Rainbow Babies & Children's Hospital, Professor of Pediatrics at Case Western Reserve University School of Medicine, and co-leader of Immune Oncology Program at Case Comprehensive Cancer Center. He also directs the Pediatric Hematology-Oncology Fellowship Program at UH Rainbow. Dr. VanHeyst is an Assistant Professor of Pediatrics at Angie Fowler AYA Cancer Institute at UH Rainbow Babies & Children's Hospital and Case Western Reserve University School of Medicine. Dr. VanHeyst has worked closely with Dr. Huang to bring a myriad of clinical trial options as direct translations from bench research to the bedside, including newly opened Phase I clinical trial using Natalizumab for treating unresectable pulmonary osteosarcoma (NCT03811886). Dr. Kristen VanHeyst completed her medical training at New York Institute of Technology School of Osteopathic Medicine, formally known as New York College of Osteopathic Medicine in 2012. She followed this with a pediatric residency at Stony Brook Children's Hospital in Stony Brook, NY, which she completed in 2015. She subsequently remained at Stony Brook Children's Hospital for an additional year to serve as a Chief Resident and Pediatric Hospitalist. Dr. VanHeyst completed her Pediatric Hematology/Oncology fellowship training in 2019 at UH Hospitals/Rainbow Babies and Children's Hospital in Cleveland, OH. As a fellow, Dr. VanHeyst joined Dr. Alex Huang's laboratory in 2017 with a primary interest in metastatic pulmonary osteosarcoma. She was appointed as an Assistant Professor of Pediatrics at Case Western Reserve University School of Medicine in 2019. Dr. VanHeyst continues her research efforts in understanding the role of the tumor microenvironment in metastatic pulmonary osteosarcoma. Based on pre-clinical data, she designed and authored a Phase I/II clinical trial using an anti-α4 monoclonal antibody as immunotherapy for pediatric, adolescent and young adult patients with relapsed, progressive and refractory disease. She hopes that continued efforts in understanding the mechanism by which metastatic osteosarcoma creates a pulmonary niche will lead to more therapeutic options for patients with this disease in the near future. Dr. VanHeyst is a recent recipient of the Hyundai Hope on Wheels Young Investigator Award and a K12 Clinical Oncology Research Program Paul Calabresi Scholar

Progression and persistence of malignancies are influenced by the local tumor microenvironment, and future eradication of currently incurable tumors will, in part, hinge on our understanding of malignant cell biology in the context of their nourishing surroundings. Article: https://www.nature.com/articles/s41590-021-00931-3 CONNECT with Trainee Committee https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee CONNECT with Madelon https://twitter.com/maadulon MORE about EBMT https://www.ebmt.org/ https://twitter.com/TheEBMT

Jordan Joiner received her Bachelors in Chemical and Biological Engineering from the University of Alabama in 2015, and she is currently a 4th year Pharmaceutical Sciences Ph.D. Candidate in the UNC Eshelman School of Pharmacy. Uniquely, before pursuing her Ph.D., Jordan worked at Evonik, a specialty chemical company, as a Process Engineer for 3 years. On this episode Jordan dives into how she made the decision to go back to university for her Ph.D. after 3 years of working in the industry, and what it's been like along the way. Links mentioned in the episode are below. Dayton Lab website: https://daytonlab.sites.unc.edu/ Benhabbour Lab website: https://benhabbour.web.unc.edu/ Jordan's Journal of Immunology paper, Focused Ultrasound for Immunomodulation of the Tumor Microenvironment: https://www.jimmunol.org/content/205/9/2327 For more information on The BME Grad Podcast, visit the Joint Department of BME at UNC and NC State's website: bme.unc.edu/home/news-events/the-bme-grad-podcast/ Connect with or reach out to Host, Allie Mitzak, on LinkedIn: www.linkedin.com/in/allie-mitzak

Jordan Joiner received her Bachelors in Chemical and Biological Engineering from the University of Alabama in 2015, and she is currently a 4th year Pharmaceutical Sciences Ph.D. Candidate in the UNC Eshelman School of Pharmacy. Uniquely, before pursuing her Ph.D., Jordan worked at Evonik, a specialty chemical company, as a Process Engineer for 3 years. On this episode Jordan dives into how she made the decision to go back to university for her Ph.D. after 3 years of working in the industry, and what it's been like along the way. Links mentioned in the episode are below. Dayton Lab website: https://daytonlab.sites.unc.edu/ Benhabbour Lab website: https://benhabbour.web.unc.edu/ Jordan's Journal of Immunology paper, Focused Ultrasound for Immunomodulation of the Tumor Microenvironment: https://www.jimmunol.org/content/205/9/2327 For more information on The BME Grad Podcast, visit the Joint Department of BME at UNC and NC State's website: bme.unc.edu/home/news-events/the-bme-grad-podcast/ Connect with or reach out to Host, Allie Mitzak, on LinkedIn: www.linkedin.com/in/allie-mitzak

Dr. Paul Peter Tak is the President and CEO of Candel Therapeutics which is focused on educating the immune system to recognize and kill tumor cells in patients with a solid tumor. Candel is developing immunotherapies using engineered oncolytic viruses for prostate cancer, brain cancer, lung cancer, pancreatic cancer, and eye cancer. Paul Peter explains, "Viruses probably got a bad reputation during the pandemic, but you can actually use them to do something beneficial to a patient, and that's what we are doing. So, using molecular engineering, we change the viruses in such a way that they infect the tumor cells and that they induce cell death. They kill the tumor cells in a way that activates the patient's own immune system, which is basically a very natural way to fight cancer." "So, at the same time, we change the so-called tumor microenvironment from a cold tumor, a tumor that is not very active in terms of immune activity, into a hot tumor where we activate a whole variety of immune cells. And that's an optimal way to immunize the patient against the patient's own variety of so-called cancer neoantigens, the molecules that are being recognized by the patient's immune system." #CandelTherapeutics #Oncology #OncolyticVirus #Immunotherapy #LungCancer #ProstateCancer #BrainCancer #Glioma #PancreaticCancer #EyeCancer #Cancer CandelTx.com Download the transcript here

Dr. Paul Peter Tak is the President and CEO of Candel Therapeutics which is focused on educating the immune system to recognize and kill tumor cells in patients with a solid tumor. Candel is developing immunotherapies using engineered oncolytic viruses for prostate cancer, brain cancer, lung cancer, pancreatic cancer, and eye cancer. Paul Peter explains, "Viruses probably got a bad reputation during the pandemic, but you can actually use them to do something beneficial to a patient, and that's what we are doing. So, using molecular engineering, we change the viruses in such a way that they infect the tumor cells and that they induce cell death. They kill the tumor cells in a way that activates the patient's own immune system, which is basically a very natural way to fight cancer." "So, at the same time, we change the so-called tumor microenvironment from a cold tumor, a tumor that is not very active in terms of immune activity, into a hot tumor where we activate a whole variety of immune cells. And that's an optimal way to immunize the patient against the patient's own variety of so-called cancer neoantigens, the molecules that are being recognized by the patient's immune system." #CandelTherapeutics #Oncology #OncolyticVirus #Immunotherapy #LungCancer #ProstateCancer #BrainCancer #Glioma #PancreaticCancer #EyeCancer #Cancer CandelTx.com Listen to the podcast here

How can cancer metastasis be better understood through the study of the microbiome? By understanding how the microenvironment reaches its most beneficial state, researchers can better understand and treat metastasis. Press play to learn:  How can cells metastasize into various parts of the body Which factors play a role in metastasis Why cancers have tropisms Sendurai A. Mani, a Professor, Department of Translational Molecular Pathology, shares his work to better understand metastasis in cancerous tumors. Since one of the most dangerous aspects of cancer is its ability to travel throughout the body, it is in researchers' and patients' best interest to discover why. This can be difficult, though, since cancer cells break the norm of normal cells. It can be challenging to distinguish single cancer cells from normal cells since they excrete the same protein. However, by explicitly studying the microenvironment, it may be easier to differentiate the cells for studies. Want to learn more? Visit https://www.mdanderson.org/research/departments-labs-institutes/labs/mani-laboratory.html. Episode also available on Apple Podcasts: apple.co/30PvU9C

To understand how cancer develops and spreads, and to develop better therapies, it’s critical to understand the tumor microenvironment, the immediate area around a tumor that “helps generate a supportive niche for it to develop and grow.” Johanna Joyce, PhD, joined the podcast to explain that the diverse normal cells around a tumor are enmeshed with cancer cells. They’re integrated. They communicate and influence each other’s functions. Her lab’s goal is “to try and either block this cellular conversation or redirect it towards a more constructive dialogue that helps fight the tumor and not support it.” Johanna Joyce, PhD, is Professor at the University of Lausanne and Full Member of the Ludwig Institute for Cancer Research. 4:32 – What is the tumor microenvironment? 6:00 – Why it’s similar to the immense complexity of a forest’s ecosystem 8:19 – Do tumors somehow create or remodel their microenvironments? 12:42 – “The tumor microenvironment can have a major impact on how a given cancer responds to therapy in a number of different ways…” 18:23 – On the unique aspects of the tumor microenvironment in the brain 22:02 – On her fantastic new study showing that different brain cancers have different microenvironments based on whether the tumors started in the brain or spread to the brain 28:15 – Surprising findings from that study – the immense complexity and diversity of immune cells in the tumor microenvironment 32:12 – How can we translate these findings to the clinic? 36:22 – Why it’s so important to understand how different lifestyles, diets, levels of activity, and environmental exposures impact patients’ tumor microenvironments 38:20 – The impact that American Cancer Society funding had on her career 40:41 – Her message for cancer patients, survivors, and caregivers

This episode, supported by Bethyl, delves into the realm of the tumor microenvironment (TME), exploring the cells that reside there and how they interact to promote tumor growth and metastasis. Discover how immune cells are attracted and manipulated by tumor cells enabling the cancer to invade neurons where they can then travel throughout the body.Providing an expert's insight into this topic is Moran Amit, Assistant Professor at the MD Anderson Cancer Center (TX, USA). Moran exposes the nebulous interactions in the TME and describes the techniques that he uses to interrogate it, in the hope that by further understanding these interactions we will be able to design more successful, targeted therapies for neurotropic cancers.Contents:· Introductions: 00:00-01:20· The key cells of the TME: 01:20-02:50· How cells of the TME support the tumor: 02:50-05:45· How cancer cells influence and impact immune cells: 05:45-07:25· The invasion of cancers into the neurons: 07:27-9:45· Recruitment of neurons to the TME: 09:45-10:55· The evolution of neuron recruitment to the TME: 10:55-15:00· Techniques involved in the study of the TME: 15:00-17:00· Tips for best practice: 17:00-18:00· Tumors with neural networks: 18:00-20:05· Clinical impact of research: 20:05-21:50· The cancers impacted the most by this research: 21:50-23:25· The impact of neural invasion on patients and neurons: 23:25-25:30· One thing to improve our understanding of the TME: 25:30-28:00 See acast.com/privacy for privacy and opt-out information.

On this week's The Sci-Files, your hosts Chelsie and Danny interview Dr. Raisa Glabman.  Dr. Glabman is a veterinarian and fellow in the NIH Comparative Biomedical Research Program (CBSTP) in partnership with MSU. As a veterinary pathology resident and Ph.D. student, she is interested in how disease pathogenesis translates across species, and in assessing the validity of specific animal models of human disease, particularly cancer immunology. Her research at NIH is centered on the stromal component of the tumor microenvironment (TME), which also includes tumor cells, immune cells, vessels, and other signaling components. Tumor stroma is critical in disease, as it forms both a physical and immunological barrier to chemotherapeutics and immunotherapy. The tumor stroma and cancer-associated fibroblasts (CAFs) in particular promote cancer progression and metastasis, leading to resistance to therapy and tumor recurrence. By selectively and locally targeting these tumor-promoting cells in murine models of human breast cancer, Dr. Glabman hopes to find new therapeutic strategies that activate the immune response in cancer patients. If you're interested in talking about your MSU research on the radio or nominating a student, please email Chelsie and Danny at scifiles@impact89fm.org. Check The Sci-Files out on Twitter, Facebook, Instagram, LinkedIn, and YouTube! 

A review paper published this month in Oncotarget by researchers from the University of Modena and Reggio Emilia in Italy and the Sulaiman AlRajhi Medical School in Saudi Arabia is trending, and titled, “Cancer stem cells and macrophages: molecular connections and future perspectives against cancer.” (Read the paper here: https://www.oncotarget.com/article/27870/text/) Two authors of this review paper, Dr. Beatrice Aramini and Dr. Valentina Masciale, provide an overview of their research on the complex crosstalk between cancer stem cells and macrophages, and potential anti-cancer strategies for future studies. The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels. (More from Trending with Impact: https://www.oncotarget.org/tag/trending-with-impact/) About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit www.oncotarget.com or connect with us on: SoundCloud - @oncotarget Facebook - www.facebook.com/Oncotarget/ Twitter - twitter.com/oncotarget LinkedIn - www.linkedin.com/company/oncotarget Pinterest - www.pinterest.com/oncotarget/ Reddit - www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.15.251959v1?rss=1 Authors: Sun, D., Wang, J., Han, Y., Dong, X., Zheng, R., Ge, J., Shi, X., Wang, B., Li, Z., Ren, P., Sun, L., Yan, Y., Zhang, P., Zhang, F., Li, T., Wang, C. Abstract: Cancer immunotherapy targeting co-inhibitory pathways by checkpoint blockade shows remarkable efficacy in a variety of cancer types. However, only a minority of patients respond to treatment due to the stochastic heterogeneity of tumor microenvironment (TME). Recent advances in single-cell RNA-seq technologies enabled comprehensive characterization of the immune system heterogeneity in tumors, but also posed computational challenges on how to integrate and utilize the massive published datasets to inform immunotherapy. Here, we present Tumor Immune Single Cell Hub (TISCH, http://tisch.comp-genomics.org), a large-scale curated database that integrates single-cell transcriptomic profiles of nearly two million cells from 76 high-quality tumor datasets across 28 cancer types. All the data were uniformly processed with a standardized workflow, including quality control, batch effect removal, malignant cell classification, cell clustering, cell-type annotation, differential expression analysis, and functional enrichment analysis. TISCH provides interactive gene expression visualization across multiple datasets at the single-cell level or cluster level, allowing systematic comparison between different cell-types, patients, tissue origins, treatment and response groups, and even different cancer-types. In summary, TISCH provides a user-friendly interface for systematically visualizing, searching, and downloading gene expression atlas in the TME from multiple cancer types, enabling fast, flexible and comprehensive exploration of the TME. Copy rights belong to original authors. Visit the link for more info

Ep. 76 Targeting the Tumor Microenvironment in HCC with Dr. Terence Gade by BackTable

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into... The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into... The post Harnessing the tumor microenvironment in lymphoma therapy appeared first on VJHemOnc.

First recorded at the 4th annual IO Combinations 360° conference, this talk provided by Dr Kenneth Hance, GSK addresses agonistic strategies, T and NK cell redirection and the use of genetic/phenotypic assocations to identify novel target space in IO. To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Join host Mary Parker as she interviews Rhiannon Jenkinson, Director of Science for Discovery Services at Charles River’s Portishead site, about this fascinating and frustrating microworld.

In this talk recorded at the 5th annual IO360° Summit, Dr Charles Link Jr, Newlink Genetics, addresses how IDO changes the T-cell balance in the tumor microenvironment. This talk addresses how: IDO creates local immunosuppression by increasing T regulatory cellsIDO often works in concert with PDL-1 mediated immunosuppressionIDO mediated T-cell immunosuppression leads to poor prognosis in melanoma Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

The pipeline of adoptive T-cell therapies and other cell based immuno-oncology programs continues to expand with a number of modifications and improvements to the first generation programs. These platforms include improved spcificty and delivery - including non-viral platforms, targeting of multiple antigens, editing constructs, and a variety of strategies to address toxicity and the tumor microenvironment. This panel of experts, moderated by Dr Gbola Amusa, Chardan and recorded at the 5th annual Immuno-Oncology 360° Summit, will consider the major technical and clinical improvements to cell based IO therapeutics that will lead to more durable therapies and the ability to treat both liquid and solid tumors. Panelists include: Dr Robert Ang, Neon TherapeuticsDr Usman "Oz" Azam, TmunityMichael Dombeck, Precision BioSciencesDr Aiman Shalabi, GSK Save the date for the 6th annual IO360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com

Prof. Dai Fukumura gives a preview of his talk, shares some challenges of reprograming tumor microenvironment and what he would like to see more in this field. For more information, please visit http://www.DiscoveryOnTarget.com/Tumor-Myeloid-Cells/

Allison is an MD, PhD and a fellow in Medical Oncology at Memorial Sloan Kettering Cancer Center. In this fascinating conversation, we talk about how exercise may affect tumor vasculature and improve the delivery of common cancer treatments. Allison’s work (along with folks such as Lee Jones) is leading the way in looking to the mechanisms of how exercise can modify the tumor microenvironment.   As a clinician, Allison talks about how the role of exercise in cancer care is viewed through the lens of oncologists. We have a great chat about how if we’re going to view exercise as medicine, we need to treat it with the same rigor we do with any other drug. A huge thanks to Allison for donating her time and offering a unique perspective to exercise oncology!

Dr. Nalini Chilkov is a leading authority and pioneer in the field of Integrative Cancer Care, cancer prevention, and immune enhancement and Founder of the American Institute of Integrative Oncology Research & Education. In this remarkable interview, we explore the “tumour microenvironment” and how environmental, lifestyle, nutritional and physiological factors influence cancer development from a practical and actionable perspective. We also explore her vision for integrative care, including empowering patients and clinician’s in evidence-based cancer prevention. Visit aiiore.com/ben & IntegrativeCancerAnswers.com.

Dr. Nalini Chilkov is a leading authority and pioneer in the field of Integrative Cancer Care, cancer prevention, and immune enhancement and Founder of the American Institute of Integrative Oncology Research & Education. In this remarkable interview, we explore the “tumour microenvironment” and how environmental, lifestyle, nutritional and physiological factors influence cancer development from a practical and actionable perspective. We also explore her vision for integrative care, including empowering patients and clinician’s in evidence-based cancer prevention. Visit aiiore.com/ben & IntegrativeCancerAnswers.com.

In this podcast from CHI on September 20, 2017, Stephen Carey speaks about Omniox’s quest to deliver oxygen into the tumor microenvironment to improve immunotherapy response. He also remarks on the challenges facing tumor microenvironment research and strategies to overcome them. To see him in person, check out the Targeting the Tumor Microenvironment conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Tumor-Microenvironment/

Norris Cotton Cancer Center Grand Rounds - Rodwell Mabaera, MD, PhD

Ralph Minter of MedImmune will describe his approach for phenotypic antibody screening and how it is being used to discover both novel antibodies and targets. He will discuss tips for overcoming obstacles to identifying novel targets, share advice for getting best results with phenotypic screening and describe how this work has been impacted by recent discoveries in the tumor microenvironment. For more information, please visit http://www.PEGSummit.com/

Background To overcome the limitations of animal-based experiments, 3D culture models mimicking the tumor microenvironment in vivo are gaining attention. Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC). Methods The potentiation effects of curcumin on 5-FU against proliferation and metastasis of HCT116 cell and its corresponding isogenic 5-FU-chemoresistant cells (HCT116R) were examined in a 3D-alginate tumor model. Results CRC cells encapsulated in alginate were able to proliferate in 3D-colonospheres in a vivo-like phenotype and invaded from alginate. During cultivation of cells in alginate, we could isolate 3 stages of cells, (1) alginate proliferating (2) invasive and (3) adherent cells. Tumor-promoting factors (CXCR4, MMP-9, NF-κB) were significantly increased in the proliferating and invasive compared to the adherent cells, however HCT116R cells overexpressed factors in comparison to the parental HCT116, suggesting an increase in malignancy behavior. In alginate, curcumin potentiated 5-FU-induced decreased capacity for proliferation, invasion and increased more sensitivity to 5-FU of HCT116R compared to the HCT116 cells. IC50 for HCT116 to 5-FU was 8nM, but co-treatment with 5 μM curcumin significantly reduced 5-FU concentrations in HCT116 and HCT116R cells (0.8nM, 0.1nM, respectively) and these effects were accompanied by down-regulation of NF-κB activation and NF-κB-regulated gene products. Conclusions Our results demonstrate that the alginate provides an excellent tumor microenvironment and indicate that curcumin potentiates and chemosensitizes HCT116R cells to 5-FU-based chemotherapy that may be useful for the treatment of CRC and to overcome drug resistance.

Thomas Rosol discusses the role of tumor microenvironment on cancer metastasis in a murine breast cancer model with Leah Schutt. Dr. Rosol coauthored the paper entitled “Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo” in the July 2014 edition of Veterinary Pathology. Dr. Rosol is a Professor and Advisor for the Life Sciences, Technology and Commercialization Office at The Ohio State University.   To view the article, click here.

Yuichi Oike discusses his research on how the tumor microenvironment promotes expression of a gene that increases the likelihood of osteosarcoma metastasis.

The January 2014 issue of Clinical Chemistry is devoted to the area of women's health. It includes a multi-center report on the application of measuring the circulating products of the proteolytic enzyme carboxypeptidase-N for the early detection of breast cancer. Accompanying that paper was an editorial by Eleftherios Diamandis on the tumor microenvironment and if released peptides could form the basis for early diagnosis breast cancer tests.

A lipid signaling enzyme promotes the growth, vascularization, and metastasis of tumors in mice.

Jeffrey Pollard, Ph.D., discusses his research into the critical role the tumor microenvironment plays in modulating cancer behavior. Dr. Pollard was recently awarded the American Cancer Society Medal of Honor for Basic Science in recognition of his research.